To report the clinical outcome after a single implant, high dose rate (HDR) brachytherapy in early prostate cancer.
All clinically localized prostate cancer patients who underwent high-dose rate (HDR) brachytherapy as monotherapy (no external beam radiotherapy) from February 2006 to September 2011 were analyzed prospectively.
Acute and chronic toxicity were assessed as per Common Terminology Criteria for Adverse Events (CTCAE), Version 4. 03. Biochemical recurrence was analyzed using the Kaplan Meir method. A log-rank analysis was done to compare the factors affecting the outcome.
Forty-four patients with organ-confined prostate cancer opted for HDR brachytherapy between February 2006 to September 2011 with a median follow-up of 68 months The five-year biochemical recurrence-free survival (bRFS) rate was 91%. Late Grade 2 genitourinary (GU) toxicity was observed in 9% of patients. The predictors of late Grade 2 GU toxicity were urethra V125 ≥ 0. 2 cc (urethral volume receiving ≥ 125% of the prescribed dose) and PTV 150 ≥ 35% ( planning target volume receiving ≥ 150% of the prescribed dose) with p-value = 0. 001 and 0. 002, respectively. Erectile function was preserved in 72% of the patients who had Grade 0-1 erectile dysfunction before brachytherapy.
HDR brachytherapy in early prostate cancer results in high local control rates with minimal side-effects.
Curēus. 2015 Aug 14*** epublish ***
Mahadev Potharaju, Ravishankar Subramanaiam, Murali Venkataraman, Karthikeyan Perumal, Balasubramaniam Ramakrishnan, Ramakrishna Vangara, Sathiya Reddy
Department of Radiation Oncology, Apollo Hospitals. , Department of Uro-Oncology, Apollo Hospitals. , Medical Physics, Apollo Hospitals. , Department of Radiation Oncology, Apollo Hospitals. , Biostatistics, Apollo Hospitals. , Department of Radiation Oncology, Apollo Hospitals. , Department of Radiation Oncology, Apollo Hospitals.